PURPOSE: The goal was to determine if prostate tumor cells containing a mutant alpha6 integrin would be defective in tumor re-population following clinically relevant fractionated ionizing radiation (IR) treatments. MATERIAL AND METHODS: Human prostate cancer cells derived from PC3N cells were used which conditionally expressed a cleavable, wild type form of alpha6 integrin (PC3N-alpha6-WT) or a mutated non-cleavable form of alpha6 integrin (PC3N-alpha6-RR). The resulting tumor growth before, during and after fractionated doses of IR (3 Gyx10 days) was analyzed using the endpoints of tumor growth inhibition (T/C), tumor growth delay (T-C), tumor doubling time (Td) and tumor cell kill (Log(10) cell kill). RESULTS: The T/C values were 36.1% and 39.5%, the T-C values were 20.5 days and 28.5 days and the Td values were 5.5 and 10.5 days for the irradiated PC3N-alpha6-WT and PC3N-alpha6-RR cells, respectively. The Log(10) was 1.1 for the PC3N-alpha6-WT cells and 0.8 for the PC3N-alpha6-RR cells. The tumor response to IR was altered in tumors expressing the mutant alpha6 integrin as indicated by a significant increase in tumor growth inhibition, an increase in tumor growth delay, an increase in tumor doubling time and an increase in tumor cell kill. CONCLUSIONS: Blocking integrin cleavage in vivo may be efficacious for increasing the IR responsiveness of slow growing, pro-metastatic human prostate cancer.
PURPOSE: The goal was to determine if prostate tumor cells containing a mutant alpha6 integrin would be defective in tumor re-population following clinically relevant fractionated ionizing radiation (IR) treatments. MATERIAL AND METHODS:Humanprostate cancer cells derived from PC3N cells were used which conditionally expressed a cleavable, wild type form of alpha6 integrin (PC3N-alpha6-WT) or a mutated non-cleavable form of alpha6 integrin (PC3N-alpha6-RR). The resulting tumor growth before, during and after fractionated doses of IR (3 Gyx10 days) was analyzed using the endpoints of tumor growth inhibition (T/C), tumor growth delay (T-C), tumor doubling time (Td) and tumor cell kill (Log(10) cell kill). RESULTS: The T/C values were 36.1% and 39.5%, the T-C values were 20.5 days and 28.5 days and the Td values were 5.5 and 10.5 days for the irradiated PC3N-alpha6-WT and PC3N-alpha6-RR cells, respectively. The Log(10) was 1.1 for the PC3N-alpha6-WT cells and 0.8 for the PC3N-alpha6-RR cells. The tumor response to IR was altered in tumors expressing the mutant alpha6 integrin as indicated by a significant increase in tumor growth inhibition, an increase in tumor growth delay, an increase in tumor doubling time and an increase in tumor cell kill. CONCLUSIONS: Blocking integrin cleavage in vivo may be efficacious for increasing the IR responsiveness of slow growing, pro-metastatic humanprostate cancer.
Authors: T L Davis; I Rabinovitz; B W Futscher; M Schnölzer; F Burger; Y Liu; M Kulesz-Martin; A E Cress Journal: J Biol Chem Date: 2001-05-18 Impact factor: 5.157
Authors: Monika Schmelz; Anne E Cress; Katherine M Scott; Friederike Bürger; Haiyan Cui; Karim Sallam; Kathy M McDaniel; Bruce L Dalkin; Raymond B Nagle Journal: Neoplasia Date: 2002 May-Jun Impact factor: 5.715
Authors: D Brouty-Boyé; H Raux; B Azzarone; A Tamboise; E Tamboise; S Béranger; V Magnien; I Pihan; L Zardi; L Israël Journal: Int J Cancer Date: 1991-03-12 Impact factor: 7.396
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Afshin Varzavand; Justin M Drake; Robert U Svensson; Mary E Herndon; Bo Zhou; Michael D Henry; Christopher S Stipp Journal: Clin Exp Metastasis Date: 2012-12-06 Impact factor: 5.150
Authors: T J Fitzgerald; Tao Wang; Hira Lal Goel; Jiayi Huang; Gary Stein; Jane Lian; Roger J Davis; Steven Doxsey; K C Balaji; Jesse Aronowitz; Lucia R Languino Journal: Expert Rev Anticancer Ther Date: 2008-06 Impact factor: 4.512
Authors: A Singer; Y Deuse; U Koch; T Hölscher; D Pfitzmann; C Jakob; S Hehlgans; G B Baretton; A Rentsch; M Baumann; M H Muders; M Krause Journal: Strahlenther Onkol Date: 2012-11-07 Impact factor: 3.621
Authors: J G Baust; D P Klossner; R G Vanbuskirk; A A Gage; V Mouraviev; T J Polascik; J M Baust Journal: Prostate Cancer Prostatic Dis Date: 2010-01-12 Impact factor: 5.554
Authors: Charles Ethan Byrne; Jean-Baptiste Decombe; Grace C Bingham; Jordan Remont; Lindsay G Miller; Layah Khalif; Connor T King; Katie Hamel; Bruce A Bunnell; Matthew E Burow; Elizabeth C Martin Journal: Tissue Eng Part A Date: 2021-04 Impact factor: 3.845
Authors: Tamara E King; Sangita C Pawar; Lisa Majuta; Isis C Sroka; Danyel Wynn; Manolis C Demetriou; Raymond B Nagle; Frank Porreca; Anne E Cress Journal: PLoS One Date: 2008-10-28 Impact factor: 3.240